FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for FSHD: new drug enters final stage of testing
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV infusion. The study measures muscle…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
FSHD patients unite: new registry aims to accelerate research and care
Knowledge-focused Recruiting nowThis study creates a registry for people with facioscapulohumeral muscular dystrophy (FSHD) to share their health experiences and data. Up to 5,000 participants in the U.S. will provide information through surveys to help researchers better understand the disease and develop impr…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Sponsor: FSHD Society • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC